文献速递临床试验与 GCP流行病学与生物统计

非布司他未延缓无症状高尿酸血症患者颈动脉粥样硬化进展:一项随机对照试验

Febuxostat does not delay progression of carotid atherosclerosis in patients with asymptomatic hyperuricemia: A randomized, controlled trial.
PubMed 文献 · PLoS Med · 2020-04-22

该多中心随机开放标签盲终点试验纳入483例无症状高尿酸血症且颈动脉最大内膜中层厚度≥1.1mm的日本成人,比较剂量滴定非布司他(10-60mg/日)与非药物生活方式干预。24个月时,两组颈总动脉平均IMT百分比变化无显著差异(组间差-0.2%,95%CI -2.3%至1.9%,P=0.83),非布司他虽显著降低血尿酸但不延缓颈动脉粥样硬化进展。

要点

  • 非布司他治疗24个月未显著延缓颈动脉IMT进展。
  • 非布司他显著降低血尿酸,但未转化为抗动脉粥样硬化获益。
  • 结果不支持对无症状高尿酸血症患者使用非布司他延缓颈动脉粥样硬化。

核心结论

  • 在日本无症状高尿酸血症患者中,24个月非布司他治疗未延缓颈动脉粥样硬化进展。
  • 这些发现不支持使用非布司他延缓该人群的颈动脉粥样硬化。

研究设计与样本

  • 多中心、前瞻性、随机、开放标签、盲终点临床试验,在日本48个中心开展。
  • 纳入无症状高尿酸血症(SUA>7.0 mg/dL)且筛查时颈总动脉最大IMT≥1.1 mm的成人。
  • 514例入组,31例排除,483例纳入改良意向治疗分析(非布司他组239例,对照组244例)。
  • 非布司他组接受剂量滴定10-60 mg/日,对照组接受非药物生活方式干预。
  • 主要终点为24个月时颈总动脉平均IMT相对基线的百分比变化,采用协方差分析校正年龄、性别、2型糖尿病史、基线SUA和基线颈总动脉最大IMT。

主要发现

  • 主要终点:非布司他组平均百分比变化1.2%(95%CI -0.6%至3.0%,n=207),对照组1.4%(95%CI -0.5%至3.3%,n=193),组间差-0.2%(95%CI -2.3%至1.9%,P=0.83)。
  • 基线颈总动脉平均IMT:非布司他组0.825 mm±0.173 mm,对照组0.832 mm±0.175 mm,组间差-0.007 mm(95%CI -0.039至0.024 mm,P=0.65)。
  • 24个月颈总动脉平均IMT:非布司他组0.832 mm±0.182 mm,对照组0.848 mm±0.176 mm,组间差-0.016 mm(95%CI -0.051至0.019 mm,P=0.37)。
  • 24个月SUA:非布司他组4.66 mg/dL±1.27 mg/dL,对照组7.28 mg/dL±1.27 mg/dL,组间差-2.62 mg/dL(95%CI -2.86至-2.38 mg/dL,P<0.001)。
  • 痛风关节炎仅发生于对照组(4例,1.6%);随访期间非布司他组死亡3例,对照组死亡7例。

临床怎么用

  • 对无症状高尿酸血症患者,不应以延缓颈动脉粥样硬化为目的使用非布司他。
  • 非布司他降低SUA的效应未转化为颈动脉IMT进展的延缓。

局限性

  • 研究设计非安慰剂对照。
  • 样本量相对较小,干预周期较短。
  • 仅纳入日本无症状高尿酸血症患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: An elevated level of serum uric acid (SUA) is associated with an increased risk of cardiovascular disease. Pharmacological intervention with urate-lowering agents, such as the conventional purine analogue xanthine oxidase (XO) inhibitor, allopurinol, has been used widely for a long period of time in clinical practice to reduce SUA levels. Febuxostat, a novel non-purine selective inhibitor of XO, has higher potency for inhibition of XO activity and greater urate-lowering efficacy than conventional allopurinol. However, clinical evidence regarding the effects of febuxostat on atherosclerosis is lacking. The purpose of the study was to test whether treatment with febuxostat delays carotid intima-media thickness (IMT) progression in patients with asymptomatic hyperuricemia. METHODS AND FINDINGS: The study was a multicenter, prospective, randomized, open-label, blinded-endpoint clinical trial undertaken at 48 sites throughout Japan between May 2014 and August 2018. Adults with both asymptomatic hyperuricemia (SUA >7.0 mg/dL) and maximum IMT of the common carotid artery (CCA) ≥1.1 mm at screening were allocated equally using a central web system to receive either dose-titrated febuxostat (10-60 mg daily) or as a control-arm, non-pharmacological lifestyle modification for hyperuricemia, such as a healthy diet and exercise therapy. Of the 514 enrolled participants, 31 were excluded from the analysis, with the remaining 483 people (mean age 69.1 years [standard deviation 10.4 years], female 19.7%) included in the primary analysis (febuxostat group, 239; control group, 244), based on a modified intention-to-treat principal. The carotid IMT images were recorded by a single sonographer at each site and read in a treatment-blinded manner by a single analyzer at a central core laboratory. The primary endpoint was the percentage change from baseline to 24 months in mean IMT of the CCA, determined by analysis of covariance using the allocation adjustment factors (age, gender, history of type 2 diabetes, baseline SUA, and baseline maximum IMT of the CCA) as the covariates. Key secondary endpoints included changes in other carotid ultrasonographic parameters and SUA and the incidence of clinical events. The mean values (± standard deviation) of CCA-IMT were 0.825 mm ± 0.173 mm in the febuxostat group and 0.832 mm ± 0.175 mm in the control group (mean between-group difference [febuxostat - control], -0.007 mm [95% confidence interval (CI) -0.039 mm to 0.024 mm; P = 0.65]) at baseline; 0.832 mm ± 0.182 mm in the febuxostat group and 0.848 mm ± 0.176 mm in the control group (mean between-group difference, -0.016 mm [95% CI -0.051 mm to 0.019 mm; P = 0.37]) at 24 months. Compared with the control group, febuxostat had no significant effect on the primary endpoint (mean percentage change 1.2% [95% CI -0.6% to 3.0%] in the febuxostat group (n = 207) versus 1.4% [95% CI -0.5% to 3.3%] in the control group (n = 193); mean between-group difference, -0.2% [95% CI -2.3% to 1.9%; P = 0.83]). Febuxostat also had no effect on the other carotid ultrasonographic parameters. The mean baseline values of SUA were comparable between the two groups (febuxostat, 7.76 mg/dL ± 0.98 mg/dL versus control, 7.73 mg/dL ± 1.04 mg/dL; mean between-group difference, 0.03 mg/dL [95% CI -0.15 mg/dL to 0.21 mg/dL; P = 0.75]). The mean value of SUA at 24 months was significantly lower in the febuxostat group than in the control group (febuxostat, 4.66 mg/dL ± 1.27 mg/dL versus control, 7.28 mg/dL ± 1.27 mg/dL; mean between-group difference, -2.62 mg/dL [95% CI -2.86 mg/dL to -2.38 mg/dL; P < 0.001]). Episodes of gout arthritis occurred only in the control group (4 patients [1.6%]). There were three deaths in the febuxostat group and seven in the control group during follow-up. A limitation of the study was the study design, as it was not a placebo-controlled trial, had a relatively small sample size and a short intervention period, and only enrolled Japanese patients with asymptomatic hyperuricemia. CONCLUSIONS: In Japanese patients with asymptomatic hyperuricemia, 24 months of febuxostat treatment did not delay carotid atherosclerosis progression, compared with non-pharmacological care. These findings do not support the use of febuxostat for delaying carotid atherosclerosis in this population. TRIAL REGISTRATION: University Hospital Medical Information Network Clinical Trial Registry UMIN000012911.

来源:PLoS Med,查看原文。版权归原作者所有。

引用

  1. Tanaka A, Taguchi I, Teragawa H, et al. Febuxostat does not delay progression of carotid atherosclerosis in patients with asymptomatic hyperuricemia: A randomized, controlled trial. PLoS Med. 2020. PMID: 32320401. doi:10.1371/journal.pmed.1003095

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。